From: Serum uric acid, disease severity and outcomes in COVID-19
Discovery cohort, n = 192 | Validation cohort, n = 325 | |||||
---|---|---|---|---|---|---|
No hypouricemia, n = 153 | Hypouricemia, n = 39 | P | No hypouricemia, n = 262 | Hypouricemia, n = 63 | P | |
Disease severity | ||||||
Classification—no. (%) | < 0.001 | < 0.001 | ||||
Mild | 13 (9) | 1 (3) | 21 (8) | 3 (5) | ||
Moderate | 32 (21) | 3 (8) | 68 (26) | 10 (16) | ||
Severe | 88 (58) | 11 (28) | 154 (59) | 21 (33) | ||
Critical | 20 (13) | 24 (62) | 19 (7) | 29 (46) | ||
Peak hsCRP, median (IQR), mg/l | 123 (65–221) | 266 (114–349) | < 0.001 | 102 (54–161) | 205 (106–302) | < 0.001 |
Nadir lymph. count, median (IQR), µl−1 | 690 (440–1000) | 410 (210–770) | < 0.001 | 785 (560–1110) | 440 (280–640) | < 0.001 |
Peak LDH, median (IQR), IU/l | 404 (318–515) | 559 (456–733) | < 0.001 | 384 (293–479) | 514 (343–746) | < 0.001 |
Outcomes | ||||||
Death—no. (%) | 31 (20) | 13 (33) | 0.1 | 27 (10) | 22 (35) | < 0.001 |
Mechanical ventilation—no. (%) | 10 (7) | 22 (56) | < 0.001 | 4 (2) | 25 (40) | < 0.001 |
Acute kidney injury—no. (%) | 17 (11) | 5 (13) | 0.8 | 13 (5) | 19 (31) | < 0.001 |
Kidney replacement therapy—no. (%) | 4 (3) | 2 (5) | 0.4 | 3 (1) | 7 (11) | < 0.001 |
Hospital LOS, median (IQR), days | 11 (6–16) | 20 (14–39) | < 0.001 | 8 (4–12) | 15 (8–38) | < 0.001 |